Management of patients with higher risk myelodysplastic syndromes

Fukumoto, Jon S.; Greenberg, Peter L.

doi:10.1016/j.critrevonc.2005.04.006

Cited by 19 publications

(21 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,3 The primary goal of treatment for higher-risk MDS is prolonging OS by altering the natural disease course. 4,5 Because treatmentrelated effects on OS may require years to measure, hematologic response has been the primary end point in most MDS clinical studies.…”

Section: Introductionmentioning

confidence: 99%

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

et al. 2013

View full text Add to dashboard Cite

The phase III AZA-001 study established that azacitidine significantly improves overall survival compared with conventional care regimens (hazard ratio 0.58 [95% confidence interval 0.43-0.77], P<0.001). This analysis was conducted to investigate the relationship between treatment response and overall survival. AZA-001 data were analyzed in a multivariate Cox regression analysis with response as a time-varying covariate. Response categories were "Overall Response" (defined as complete remission, partial remission, or any hematologic improvement) and "Stable Disease" (no complete or partial remission, hematologic improvement, or progression) or "Other" (e.g. disease progression). Achieving an Overall Response with azacitidine reduced risk of death by 95% compared with achieving an Overall These results demonstrate azacitidine benefit on overall survival compared with conventional care regimens in patients with higher-risk myelodysplastic syndromes who achieve hematologic response but never attain complete or partial remission, in addition to the survival advantage conferred by achievement of complete or partial remission. This study was registered with clinicaltrials.gov (NCT00071799).A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

show abstract

Section: Introductionmentioning

confidence: 99%

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Previous large studies using various induction regimens containing AraC in various combinations with idarubicin, fludarabine, topotecan, and cyclophosphamide demonstrated CR rates of ~40-60% for higher-risk MDS, median OS rate 10.4-13 months, and treatment-related early death 10-20% (2,3,26,27). In the present study, an HAA regimen was implemented for MDS-RAEB in adults who were aged 18-66 years.…”

Section: Discussionmentioning

confidence: 72%

“…Patients with higher-risk MDS, which include intermediate-2 and high risk of the International Prognostic Scoring System (IPSS), have a peculiar propensity to evolve into acute myeloid leukemia (AML), and often have a median survival time of <12 months (2,3). Currently, hypomethylating agents (such as azacitidine and decitabine), lenalidomide, intensive chemotherapy, and allo-hematopoietic stem cell transplantation may be therapeutic options for patients with higher-risk MDS (4).…”

Section: Introductionmentioning

confidence: 99%

“…Currently, hypomethylating agents (such as azacitidine and decitabine), lenalidomide, intensive chemotherapy, and allo-hematopoietic stem cell transplantation may be therapeutic options for patients with higher-risk MDS (4). However, high-intensity chemotherapy is generally reserved for higher-risk patients, particularly young patients eligible for intensive therapy that lack a suitable stem cell donor (2,5). Unfortunately, treatment of MDS patients with chemotherapy only results in a few long-term survivors (2,5,6).…”

Section: Introductionmentioning

confidence: 99%

“…However, high-intensity chemotherapy is generally reserved for higher-risk patients, particularly young patients eligible for intensive therapy that lack a suitable stem cell donor (2,5). Unfortunately, treatment of MDS patients with chemotherapy only results in a few long-term survivors (2,5,6). Therefore, innovative approaches for the treatment of higher-risk MDS should be developed.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB

Xiao

Liu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the treatment outcome of homoharringtonine, cytarabine (AraC) and aclarubicin combination therapy as induction treatment for myelodysplastic syndromes-refractory anemia with excess blasts (MDS-RAEB). A total of 24 patients with MDS-RAEB who were aged between 18 and 66 years were treated with homoharringtonine, AraC and aclarubicin (HAA regimen). The HAA regimen consisted of homoharringtonine (2 mg/m 2 intramuscularly twice daily, days 1-3), AraC (75 mg/m 2 injected subcutaneously twice daily, days 1-7) and aclarubicin (12 mg/m 2 , days 1-7). The overall response rate was 79% with a complete remission rate of 58.3% and partial remission rate of 20.7%. There was no evidence of early mortality in this group of patients. The median overall survival (OS) was 36.2 months (95% confidence interval, 24.6-47.4 months), and the estimated three year overall survival rate was 45.8%. In conclusion, HAA combination therapy is a suitable induction regimen for patients with MDS-RAEB, which may improve the outcome for de novo higher-risk MDS patients, particularly of those with favorable and intermediate cytogenetics.

show abstract

Current Awareness in Hematological Oncology

2006

Hematological Oncology

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of hematological oncology. Each bibliography is divided into 14 sections: 1 Books, Reviews & Symposia; 2 General; Leukemias: 3 Lymphoblastic; 4 Myeloid & Myelodysplastic Syndromes; 5 Chronic; 6 Others; Lymphomas: 7 Hodgkin's; 8 Non‐Hodgkin's; 9 Plasmacytomas/Multiple Myelomas; 10 Others; 11 Bone Marrow Transplantation; 12 Cytokines; 13 Diagnosis; 14 Cytogenetics. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Management of patients with higher risk myelodysplastic syndromes

Cited by 19 publications

References 78 publications

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB

Current Awareness in Hematological Oncology

Contact Info

Product

Resources

About